ArticleInternational journal of general medicine2025
Pyroptosis-Mediator GSDMD in Plasma: A Potent Biomarker Lung Cancer Diagnosis and Prognosis Assessment.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Lung cancer's high mortality is linked to late diagnosis, with current methods having limitations. This study aimed to evaluate the diagnostic efficacy of Gasdermin D (GSDMD) in lung cancer and explore its biological functions. Methods: A total of 114 lung cancer patients, 87 patients with pulmonary nodules, and 100 healthy controls were enrolled. Clinical data were collected, and venous blood samples were obtained. GSDMD, carcinoembryonic antigen (CEA), neuron - specific enolase (NSE), cytokeratin 19 fragment (CYFRA21 - 1), and other markers were measured using specific assays. Statistical analysis, including variance tests, ANOVA, and logistic regression, was performed to analyze the data. Results: There were no significant differences in age and gender among the three groups. However, GSDMD levels were highest in the lung cancer group, followed by the pulmonary nodule group, and lowest in the healthy control group ( Conclusion: GSDMD holds promise as a diagnostic/prognostic biomarker for lung cancer, alone or combined with other markers, enhancing risk assessment accuracy to aid early detection and improve outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.